Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence

An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment... ORIGINAL ARTICLE An Evaluation of µ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study Raymond F. Anton, MD; Gabor Oroszi, MD, PhD; Stephanie O’Malley, PhD; David Couper, PhD; Robert Swift, MD, PhD; Helen Pettinati, PhD; David Goldman, MD Context: Naltrexone hydrochloride treatment for alco- Main Outcome Measures: Time trends in percent- hol dependence works for some individuals but not for age of days abstinent, percentage of heavy drinking days, and rates of good clinical outcome. everyone. Asn40Asp, a functional polymorphism of the µ-opioid receptor gene (OPRM1), might predict naltrex- Results: Alcoholic subjects with an Asp40 allele receiv- one response. ing MM alone (no CBI) had an increased percentage of days abstinent (P=.07) and a decreased percentage of Objective: To evaluate whether individuals with alco- heavy drinking days (P=.04) if treated with naltrexone holism who are heterozygous (Asp40/Asn40) or homo- vs placebo, while those with the Asn40/Asn40 genotype zygous (Asp40/Asp40) for the OPRM1 Asp40 allele re- showed no medication differences. If treated with MM spond better to naltrexone. alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence

Download PDF
10 pages

Loading next page...
 
/lp/american-medical-association/an-evaluation-of-opioid-receptor-oprm1-as-a-predictor-of-naltrexone-kS0nN77Y4N

References (70)

Publisher
American Medical Association
Copyright
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/archpsyc.65.2.135
pmid
18250251
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE An Evaluation of µ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study Raymond F. Anton, MD; Gabor Oroszi, MD, PhD; Stephanie O’Malley, PhD; David Couper, PhD; Robert Swift, MD, PhD; Helen Pettinati, PhD; David Goldman, MD Context: Naltrexone hydrochloride treatment for alco- Main Outcome Measures: Time trends in percent- hol dependence works for some individuals but not for age of days abstinent, percentage of heavy drinking days, and rates of good clinical outcome. everyone. Asn40Asp, a functional polymorphism of the µ-opioid receptor gene (OPRM1), might predict naltrex- Results: Alcoholic subjects with an Asp40 allele receiv- one response. ing MM alone (no CBI) had an increased percentage of days abstinent (P=.07) and a decreased percentage of Objective: To evaluate whether individuals with alco- heavy drinking days (P=.04) if treated with naltrexone holism who are heterozygous (Asp40/Asn40) or homo- vs placebo, while those with the Asn40/Asn40 genotype zygous (Asp40/Asp40) for the OPRM1 Asp40 allele re- showed no medication differences. If treated with MM spond better to naltrexone. alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared

Journal

JAMA Psychiatry – American Medical Association

Published: Feb 1, 2008

There are no references for this article.